Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.83) by 4.82 percent. This is a 11.24 percent increase over losses of $(0.89) per share from the same period last year.
Raymond James Maintains Outperform on Xenia Hotels & Resorts, Lowers Price Target to $20
Raymond James analyst William Crow maintains Xenia Hotels & Resorts (NYSE:XHR) with a Outperform and lowers the price target from $22 to $20.
